{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    4,
    6,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_9",
        "affectedSection": "Synopsis; Section 3.1; Section 10.1; Section 11.2; Section 11.3; Section 17.9.1",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Redefinition of clinical cut-off for final CSR analysis and transition to long-term survival follow-up."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_9",
        "affectedSection": "Section 8.2; Section 8.3",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Clarification of permitted and prohibited vaccinations, specifically regarding live-attenuated vaccines."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_8",
        "affectedSection": "Synopsis; Section 3.1; Section 6.1.3",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Introduction of Subcutaneous (SC) daratumumab administration as an alternative to Intravenous (IV) during COVID-19."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_6",
        "affectedSection": "Time and Events Schedule; Section 8.1.7; Section 9.8",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Implementation of Hepatitis B Virus (HBV) screening and monitoring due to new identified risk of reactivation."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_9",
        "reasonText": "To define the clinical cut-off for the final CSR analysis and timing of final OS analysis.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_8",
        "reasonText": "To provide flexibility for investigators to prioritize patient safety during the global COVID-19 pandemic.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_6",
        "reasonText": "In response to identification of a new important risk (hepatitis B virus [HBV] reactivation).",
        "category": "Safety",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_5",
        "reasonText": "IDMC recommendation following positive second interim analysis to allow Arm A subjects access to daratumumab.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_9",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "17.9.1",
        "beforeText": "end of the study",
        "afterText": "until the final OS analysis",
        "summary": "Updated terminology to distinguish between final OS analysis and the actual end of study."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_9",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "12.1.1",
        "beforeText": "null",
        "afterText": "Second primary malignancies added to medically important events.",
        "summary": "Expanded definition of medically important serious adverse events."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_8",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1.3",
        "beforeText": "null",
        "afterText": "Daratumumab SC 1800 mg administration",
        "summary": "Added subcutaneous route of administration for daratumumab."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_6",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.4.1.2",
        "beforeText": "Standard dose delay language",
        "afterText": "Subjects whose dose was delayed for more than 4 weeks (Cycle 1 to 6) or 6 weeks (Cycle 7+) should have study treatment discontinued unless sponsor agrees otherwise.",
        "summary": "Tightened requirements for treatment discontinuation due to prolonged dose delays."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_5",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "8.4",
        "beforeText": "null",
        "afterText": "Subjects randomized to Arm A (Rd) who have sponsor-confirmed disease progression may have the option to receive daratumumab.",
        "summary": "Added provision for cross-over/subsequent daratumumab therapy for the control arm."
      }
    ],
    "summary": {
      "impactCount": 4,
      "reasonCount": 4,
      "changeCount": 5
    }
  }
}